Under the agreement, BioSeek will apply its unique BioMAP predictive human disease models to screen Amylin’s phormol library to discover peptides with a potential for treatment of a range of inflammatory conditions. This collaboration follows similar agreements in recent years between the two companies involving peptide screening and related drug discovery activities.

BioMAP Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology.

Martyn Coombs, CEO of Asterand, said: “Our BioMAP human-based disease model is well-suited to assist Amylin in its search for new innovative treatments for inflammation. We look forward to assisting Amylin with this latest project, and other similar collaborations in the future.”

Will BioSeek benefit with this agreement?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.